Metraipolis › archive › dc_c50bb5ea16af

Therapeutic potential of the Nrf2 activator omaveloxolone in spinocerebellar ataxia type 3 in cellular and Drosophila models — Europe PMC PMID:42621215

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42621215
DOI: 10.3389/fphar.2026.1872142
License (as archived): solo-consultazione
Archived: 2026-10-17T01:37:03.452Z
SHA-256 of the archived text: ac1f03b2239f95dc5f817ad820c24416f7d6598c3483881e543a08a557801b4f
Stable URL of this page: https://metraipolis.com/documento/dc_c50bb5ea16af

How to cite

Therapeutic potential of the Nrf2 activator omaveloxolone in spinocerebellar ataxia type 3 in cellular and Drosophila models — Europe PMC PMID:42621215 — Europe PMC (en), https://europepmc.org/article/MED/42621215 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c50bb5ea16af (Metraipolis archive dc_c50bb5ea16af, sha256 ac1f03b2239f95dc5f817ad820c24416f7d6598c3483881e543a08a557801b4f)

BibTeX

@misc{dcc50bb5ea16af,
  title = {Therapeutic potential of the Nrf2 activator omaveloxolone in spinocerebellar ataxia type 3 in cellular and Drosophila models — Europe PMC PMID:42621215},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42621215},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c50bb5ea16af; sha256 ac1f03b2239f95dc5f817ad820c24416f7d6598c3483881e543a08a557801b4f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42621215. Agents can read the archived copy with the MCP tool read_document.